Clinical trial
Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line…
NCT00430001 · Danish Breast Cancer Cooperative Group, Other · Unknown status
Key facts
| NCT number | NCT00430001 |
|---|---|
| Title | Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer |
| Official title | A Randomised Phase III Study of Trastuzumab-Docetaxel vs Trastuzumab-Vinorelbine as 1. Line Therapy for Patients With Metastatic HER2 Positive Breast Cancer |
| Lead sponsor | Danish Breast Cancer Cooperative Group, Other |
| Collaborators | Hoffmann-La Roche Industry Sanofi |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, vinorelbine, trastuzumab |
| Enrollment | 300 |
| Start date | May 1, 2005 |
| Completion | Dec 1, 2008 |
| First posted | Feb 1, 2007 |
| Last update posted | May 9, 2008 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: